Supriya Lifescience Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Supriya Lifescience Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹90Over the last 3 years, every ₹100 of reported profit came with ₹90 of operating cash.
Lower than 60% of Healthcare companies in India.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash covered its investment spending (capex) 1.0 times.
Lower than 65% of Healthcare companies in India.
Cash Locked Ratio
₹33For every ₹100 of sales, ₹33 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹30 tied up three years earlier.
More money tied up than 68% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹34Sales grew 78% in 3 years; of every extra ₹100 of sales, ₹34 became extra profit.
Higher than 82% of Healthcare companies in India.
Asset Productivity Ratio
+78% / +65%In 3 years sales changed by +78% while total assets changed by +65%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 66% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 83% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 84% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Supriya Lifescience Limited owes ₹0.12 for every ₹1 it owns. Net profit rose 11% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
33.9Investors pay ₹33.9 for every ₹1 of Supriya Lifescience Limited's yearly profit, lower than 56% of Healthcare companies in India.
P/B ratio
5.62The share price is 5.62 times Supriya Lifescience Limited's book value per share, higher than 62% of Healthcare companies in India.
Market cap
₹6,730 CrThe total market value of all of Supriya Lifescience Limited's shares at today's price (share price × number of shares), larger than 55% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,198 CrWhat Supriya Lifescience Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹148.82Net worth divided by the number of shares. The share price of ₹836.25 is 5.6 times this, which is the P/B above.
Return on equity (ROE)
16.6%Supriya Lifescience Limited earned 16.6% on its shareholders' money over the last year, higher than 64% of Healthcare companies in India.
Owes vs Owns
0.12×Supriya Lifescience Limited owes ₹0.12 for every ₹1 it owns (low), lower than 97% of Healthcare companies in India.
Dividend yield
0.12%Supriya Lifescience Limited pays 0.12% of its share price as dividends a year, lower than 84% of dividend-paying Healthcare companies in India.
Revenue growth
+18%Revenue rose 18% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Profit growth
+11%Net profit rose 11% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Profit margin
26.1%Supriya Lifescience Limited keeps ₹26 of every ₹100 of revenue as net profit.
Cash quality
0.9×Cash from Supriya Lifescience Limited's business was 0.9× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
182.5×Supriya Lifescience Limited's operating profit covered its interest costs 182.5 times in the year to Mar 2026.
Cash vs debt
Net cashSupriya Lifescience Limited held ₹73 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Supriya Lifescience Limited's P/E ratio?
Investors pay ₹33.9 for every ₹1 of Supriya Lifescience Limited's yearly profit, lower than 56% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Supriya Lifescience Limited: ₹6,730 Cr ÷ ₹1,198 Cr (31 Mar 2026) = 5.6.
What is Supriya Lifescience Limited's return on equity?
Supriya Lifescience Limited earned 16.6% on its shareholders' money over the last year, higher than 64% of Healthcare companies in India.
How much does Supriya Lifescience Limited owe compared with what it owns?
Supriya Lifescience Limited owes ₹0.12 for every ₹1 it owns (low), lower than 97% of Healthcare companies in India.
Does Supriya Lifescience Limited pay a dividend?
Yes. Supriya Lifescience Limited pays 0.12% of its share price as dividends a year, lower than 84% of dividend-paying Healthcare companies in India.
Is Supriya Lifescience Limited's revenue growing?
Revenue rose 18% in the year to Mar 2026, and grew 21% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.